Shoddy biopsies deny cancer patients a shot at personalized treatment
Elie Dolgin • January 22, 2016
A huge federal trial of personalized cancer medicine has run into an unexpected roadblock: Many of the tumor samples aren’t robust enough to be put through genetic analysis.
Continue reading at
STAT.
Circulating biomarkers are quickly becoming a crucial part of diagnosis and disease monitoring for physicians, researchers — and even some consumers.
Zebras and giraffes offer one another protection without food competition.